CN101287829A - 治疗孤独症的组合物和方法 - Google Patents

治疗孤独症的组合物和方法 Download PDF

Info

Publication number
CN101287829A
CN101287829A CNA2005800476252A CN200580047625A CN101287829A CN 101287829 A CN101287829 A CN 101287829A CN A2005800476252 A CNA2005800476252 A CN A2005800476252A CN 200580047625 A CN200580047625 A CN 200580047625A CN 101287829 A CN101287829 A CN 101287829A
Authority
CN
China
Prior art keywords
composition
transglucosidase
glucoamylase
group
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800476252A
Other languages
English (en)
Chinese (zh)
Inventor
J·B·蓬博恩
L·纽曼
R·梅德卡
A·科利尔
S·马尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL ENZYME COMPANY Inc
Kirkman Group Inc
Original Assignee
NATIONAL ENZYME COMPANY Inc
Kirkman Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL ENZYME COMPANY Inc, Kirkman Group Inc filed Critical NATIONAL ENZYME COMPANY Inc
Publication of CN101287829A publication Critical patent/CN101287829A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01024—1,4-Alpha-glucan 6-alpha-glucosyltransferase (2.4.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
CNA2005800476252A 2004-12-01 2005-11-30 治疗孤独症的组合物和方法 Pending CN101287829A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/000,668 2004-12-01
US11/000,668 US20060115467A1 (en) 2004-12-01 2004-12-01 Compositions and methods for the treatment of autism

Publications (1)

Publication Number Publication Date
CN101287829A true CN101287829A (zh) 2008-10-15

Family

ID=36565652

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800476252A Pending CN101287829A (zh) 2004-12-01 2005-11-30 治疗孤独症的组合物和方法

Country Status (8)

Country Link
US (2) US20060115467A1 (https=)
EP (1) EP1817052A4 (https=)
JP (1) JP2008521906A (https=)
CN (1) CN101287829A (https=)
AU (1) AU2005311975A1 (https=)
CA (1) CA2590384A1 (https=)
WO (1) WO2006060414A2 (https=)
ZA (1) ZA200704677B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144698A (zh) * 2012-01-03 2014-11-12 柯尔马克有限责任公司 治疗神经和精神障碍的行为症状的方法
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
PT2016838T (pt) * 2007-06-18 2017-08-28 Et & Ds Company Ltd Suplemento alimentar
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2009134964A2 (en) * 2008-04-30 2009-11-05 Danisco Us Inc. Enhanced fermentation process using molasses
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2443259A4 (en) * 2009-06-16 2012-10-10 Univ Columbia BIOMARKERS ASSOCIATED WITH AUTISM AND USES THEREOF
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP2504025A4 (en) * 2009-11-23 2013-05-01 Stephen F Olmstead COMPOSITIONS AND METHODS USING SERRATIA PEPTIDASE FOR INHIBITING AND TREATING BIOFILMS ASSOCIATED WITH PARTICULAR SUFFERING
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10195256B2 (en) 2015-12-14 2019-02-05 Thea Fournier Enzyme formulation for reducing salicylate and other intolerance
US9775887B2 (en) * 2015-12-14 2017-10-03 Thea Fournier Enzyme formulation for reducing salicylate intolerance
GB201614415D0 (en) 2016-08-24 2016-10-05 Pepsis Ltd Enzymes for the treatment of human enterometabolic dysfunction
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
TWI658791B (zh) * 2017-09-25 2019-05-11 愛之味股份有限公司 具有調節血脂、改善腸道菌叢及提升免疫力功能的富含寡醣乳製品及其製法
EP3927180A1 (en) * 2019-02-19 2021-12-29 DSM IP Assets B.V. Method for reducing fructan in a food product with aid of invertase (ec 3.2.1.26)
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023115212A1 (en) * 2021-12-23 2023-06-29 Access Nutrients Inc. Prevention and treatment of diseases using phytase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042823A (en) * 1998-07-02 2000-03-28 Amano Pharmaceuticals Co., Ltd. Enzyme composition and use thereof
US6783757B2 (en) * 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104144698A (zh) * 2012-01-03 2014-11-12 柯尔马克有限责任公司 治疗神经和精神障碍的行为症状的方法
CN108578684A (zh) * 2012-01-03 2018-09-28 柯尔马克有限责任公司 治疗神经和精神障碍的行为症状的方法
CN105652016A (zh) * 2016-01-28 2016-06-08 深圳大学 一种孤独症检测标志物及其检测方法

Also Published As

Publication number Publication date
ZA200704677B (en) 2008-09-25
US20060115467A1 (en) 2006-06-01
AU2005311975A1 (en) 2006-06-08
EP1817052A2 (en) 2007-08-15
US20080112944A1 (en) 2008-05-15
CA2590384A1 (en) 2006-06-08
JP2008521906A (ja) 2008-06-26
WO2006060414A2 (en) 2006-06-08
EP1817052A4 (en) 2008-07-02
WO2006060414A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
CN101287829A (zh) 治疗孤独症的组合物和方法
US6783757B2 (en) Composition and method for increasing exorphin catabolism to treat autism
Jung et al. The presence of resistant starch-degrading amylases in Bifidobacterium adolescentis of the human gut
EP1694273B1 (en) Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6051220A (en) Composition to improve digestibility and utilization of nutrients
US20040057944A1 (en) Microbial enzyme mixtures useful to treat digestive disorders
US5445957A (en) Enzyme food supplement composition containing beta-fructofuranosidase, cellulase and hemicellulase
Lin et al. Direct starch digestion by sucrase-isomaltase and maltase-glucoamylase
Swami et al. Functional dyspepsia and the role of digestive enzymes supplement in its therapy
Garvey et al. Fungal digestive enzymes promote macronutrient hydrolysis in the INFOGEST static in vitro simulation of digestion
JP2014516032A (ja) 健康補助食品
US10159721B2 (en) Enzyme formulation for use as food supplement
CA2055506C (en) Composition and method for reducing gastro-intestinal distress due to alpha-d-galactoside-linked/containing sugars
JP5317501B2 (ja) 疲労軽減剤
US11202810B2 (en) Stable probiotic composition for the management of lactose intolerance
US20170000830A1 (en) Compositions for Relieving the Symptoms of Gluten Sensitivity and Methods of Use Thereof
CN116456841A (zh) 果糖基转移酶的用途
Zárate et al. Feeding with dairy Propionibacterium acidipropionici CRL 1198 reduces the incidence of Concanavalin-A induced alterations in mouse small intestinal epithelium
WO2020204910A1 (en) Stable probiotic composition for the management of lactose intolerance
Fara et al. In vitro digestibility of oligosaccharides synthesized by dairy propionibacteria β-galactosidase from lactose, lactulose and lactitol
Paliulis et al. Protease, amylase and lactase enzyme stability in Gastroval® capsules after incubation at acidic pH and elevated temperature
JP7813454B2 (ja) 経口用組成物
JP5717433B2 (ja) 胆汁酸吸着用組成物
Ekun et al. Glycine max Seed Protein Hydrolysates: Antiglycation Potentials and Inhibition of Carbohydrate-hydrolyzing Enzymes
Las PC Digestive Enzymes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081015